作为潜在的ERK2抑制剂,天然存在的植物性抗癌候选物:基数据库采矿和分子动力学模拟
Mahmoud A A Ibrahim1,2, Sara S M Ali1, Alaa H M Abdelrahman1
1Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia, 61519, Egypt.
我们选了1500多种植物化合物,寻找潜在的细胞外信号调节激酶2 (ERK2) 抑制剂. 尚库酸C显示出优越的结合亲和力和最小的毒性,表明它是一个有前途的ERK2抑制剂候选者.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 计算化学的计算化学
背景情况:
- 细胞外信号调节激酶2 (ERK2) 对细胞信号传递和人类发育至关重要.
- ERK2过活化与瘤进展有关,但目前还没有批准的抑制剂.
- 准ERK2为癌症治疗提供了治疗机会.
研究的目的:
- 从天然产品数据库中识别新型ERK2抑制剂.
- 用计算方法评估潜在抑制剂的结合亲和力和稳定性.
主要方法:
- 从NPACT数据库中选超过1500种植物化学物质,使用in-silico分子对接.
- 分子动力学 (MD) 模拟和MM-GBSA计算以评估结合能.
- 在中预测ADMET用于毒性评估.
主要成果:
- 尚库酸C (NPACT01034) 与参考抑制剂LHZ相比,对ERK2的结合亲和力更高 (-50.0对比-47.7kcal/mol).
- MD模拟证实了木酸C和ERK2.2之间的稳定复合体形成.
- 在中ADMET分析预测了C. zhankuic酸的最小毒性.
- 在临床试验中,Zhankuic acid C与14种ERK2抑制剂相比,显示出更高的结合亲和力.
结论:
- 木酸C是一种强大的天然化合物,具有对ERK2.2的高结合亲和力.
- 它的稳定复合形成和有利的预测ADMET特性使其成为进一步开发作为抗癌治疗药物的有希望的候选者.
- 这项研究强调了天然产品在药物发现中的潜力,以准关键信号通路.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
相关概念视频
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Prevention
Some...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
